HTA226 Can Prior Indirect Treatment Comparisons (ITCs) Inform Health Technology Assessment (HTA) Strategy: A Case Study in Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.1909
https://www.valueinhealthjournal.com/article/S1098-3015(23)05039-8/fulltext
Section Title :
Section Order :
11354
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05039-8&doi=10.1016/j.jval.2023.09.1909